Legal-Graphics' 5-17-21 COVID Timeline

Total Page:16

File Type:pdf, Size:1020Kb

Legal-Graphics' 5-17-21 COVID Timeline Number of days since Overview: Year 2 of COVID first sign of virus Year 2 Nov. 23, 2020 Dec. 3, 2020 Dec. 11, 2020 Dec. 21, 2020 Dec. 30, 2020 Jan. 7, 2021 Jan.Jan. 14,7, 2021 2021 of COVID-19 Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths over 1,400,000 over 1,500,000 over 1,600,000 over 1,700,000 over 1,800,000 over 1,900,000 over 1,900,0002,000,000 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 Link to Nov. 16, 2020 Nov. 18, 2020 Nov. 21, 2020 Nov. 25, 2020 Nov. 27, 2020 Nov. 30, 2020 Dec. 3, 2020 Dec. 6, 2020 Dec. 8, 2020 Dec. 11, 2020 Dec. 14, 2020 Dec. 17, 2020 Dec. 21, 2020 Dec. 22, 2020 Dec. 26, 2020 Dec. 29, 2020 Dec. 31, 2020 Jan. 3, 2021 Jan. 5, 2021 Jan. 8, 2021 Jan. 11, 2021 Jan. 13, 2021 Jan. 17, 2021 Source Moderna says data FDA allows US cases top Picture of US Demand for live Moderna to request Map showing US UK gears up for Chart of cumulative Pfizer vaccine to be How do the Pfizer Vaccinations reach How the Pfizer Vaccines across Could AZD7442 Map showing How vaccinations Interactive US Map It’s lockdown No. 3 Pfizer vaccine Japan has found Initial Israeli data: Vaccine skepticism shows its vaccine 1st rapid virus test 12 million ... spread economy is Christmas trees emergency states with the huge vaccination number of deaths OK’d in days - and Moderna US nursing homes and Moderna the world prevent COVID-19 which countries were developed by county showing for England, at least appears effective a new Covid variant First Pfizer shot hurts East European Signs of Virus is more than that gives results 'faster' and 'broader' worrisome skyrockets amid authorization their highest number plan watched by country (by “normal” next fall vaccines work? vaccines compare infection have rolled out so quickly risk for COVID six weeks at home against mutation in curbs infections by anti-virus efforts at home as virus toll of virus number of days a COVID-19 vaccine new virus variants 50% after 14 days 94% effective than ever coronavirus vaccine of virus deaths by the world in those exposed? Jan. 11, 2021 Key Events inflicts damage since 100 deaths Dec. 18, 2020 Dec. 22, 2020 Dec. 31, 2020 Jan. 6, 2021 Jan. 17, 2021 Dec. 12, 2020 Dec. 15, 2020 Dec. 21, 2020 Jan. 4, 2021 US vaccine rollout US virus deaths Vaccines across Dec. 30, 2020 Jan. 9, 2021 Jan. 14, 2021 Dec. 1, 2020 Dec. 4, 2020 Dec. 7, 2020 Dec. 27, 2020 Where the world problematic Elderly hunger is Good News! Nov. 17, 2020 Nov. 19, 2020 Nov. 23, 2020 Nov. 28, 2020 Experts to consider and cases set Variant of virus 82 year old EU agency approves Dec. 9, 2020 Tracking nine of the US Nov. 26, 2020 The European Union records spreading across December is the Britain becomes 1st stands on dialysis patient Moderna vaccine US vaccine rollout STUDY: Recovering on the rise Governors ratchet > 900 Mayo Clinic AstraZeneca vaccine United Airlines Job growth China prepares the most promising approving Moderna Legal Matters eyes Dec 29, 2020 UK sending it deadliest month country to approve vaccination rollout gets first hits a snag from Covid gives during Covid up restrictions staff diagnosed (which only needs Macy’s is flying Pfizer slows sharply large-scale rollout US Hospitals under COVID-19 vaccines vaccine for US Jan. 11, 2021 approval for into “Tier Four” Dec. 23, 2020 in the US since the AstraZeneca vaccine AstraZeneca jab similar level of ahead of with COVID-19 to be refrigerated Thanksgiving Day COVID-19 vaccine as pandemic takes of coronavirus “extreme stress” Jan. 6, 2021 Dec. 19, 2020 lockdown coronavirus In US, Oklahoma’s protection to vaccine Oklahoma Events Thanksgiving - not frozen, like Parade marches on! 1st virus vaccine toll on economy vaccines and “overloaded” Jan. 1, 2021 Jan. 9, 2021 Jan. 18, 2021 Thailand grapples pandemic began Vaccine refusers scheduling portal Pfizer and Moderna) Dec. 13, 2020 Dec. 16, 2020 How many COVID-19 Dec. 30, 2020 Jan. 4, 2021 with virus outbreak may be limited Queen launches Israel trades Pfizer Economic News found to be 70-90% vaccines has each Demand for Jan. 15, 2021 Nov. 29, 2020 Dec. 2, 2020 Dec. 5, 2020 Canada secures Dec. 21, 2020 1st US case of virus Britain's jab blitz doses for effective Nov. 26, 2020 Dec. 10, 2020 Historic U.S. COVID country bought? rescue animals US vaccine Jan. 12, 2021 vaccine campaign early doses from Dec. 27, 2020 variant detected has skyrocketed administation Tracking US medical data Pandemic The 5 US states Moscow opens US Congress Dec. 23, 2020 Jan. 7, 2021 Hospitalizations launches with Moderna in Colorado tracker Irish infection rate COVID vaccine calls off Christmas with the most dozens of Sweden pulls a seals agreement “Hug booth” allows Jan. 10, 2021 in the US convoy of trucks US reports highest “world’s highest” distribution by state markets in Europe hospitalizations coronavirus U-turn and proposes on $900 billion US buys more doses nursing home hit another record Jan. 2, 2021 single-day death toll vaccination centers a lockdown law COVID relief bill of Pfizer vaccine residents to touch Johnson under fire as UK again faces Dec. 2, 2020 Dec. 13, 2020 their loved ones Jan. 12, 2021 Israel leads vaccine onslaught of Jan. 16, 2021 race with 12% Dec. 24, 2020 COVID-19 US reports its COVID-19 vaccine given jab Potential super China has suffered highest one-day in Oklahoma: spreader event a surge of cases www.legalgraphics.net death tally: Who gets it first? Santa Claus since December Over 2,800 is “good to go!” Overview: Year 1 of COVID Jan.Jan. 22,7, 2021 2021 Jan.Jan. 29,7, 2021 2021 Feb. 5, 2021 Feb. 13, 2021 Feb. 24, 2021 Mar. 7, 2021 Mar. 18, 2021 Mar. 29, 2021 Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths over 1,900,0002,100,000 over 1,900,0002,200,000 over 2,300,000 over 2,400,000 over 2,500,000 over 2,600,000 over 2,700,000 over 2,800,000 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 Jan. 19, 2021 Jan. 22, 2021 Jan. 25, 2021 Jan. 28, 2021 Jan. 31, 2021 Feb. 2, 2021 Feb. 5, 2021 Feb. 7, 2021 Feb. 10, 2021 Feb. 13, 2021 Feb. 16, 2021 Feb. 17,19, 2021 Feb. 17,22, 2021 Feb. 17,25, 2021 Feb. 17,27, 2021 Feb.Mar. 17,2, 2021 2021 Feb.Mar. 17,5, 2021 2021 Feb.Mar. 17,8, 2021 2021 Feb.Mar. 17,11, 2021 Feb.Mar. 14,17, 2021 Feb.Mar. 16,17, 2021 Feb.Mar. 19,17, 2021 Feb.Mar. 22,17, 2021 Feb.Mar. 25,17, 2021 Feb.Mar. 28,17, 2021 A new COVID-19 Lucky few hit Bernie happy his How is the COVID-19 US hospitalizations Israel's vaccine Johnson &Johnson Richer countries The US needs more Should you mix and India’s dramatic fall How the US states US death toll Comparing the Diagram of the Chinese vaccines Countries making FDA issues EUA Israel’s cases drop AstraZeneca’s EU Flashcards for Uptick of infections AstraZeneca vaccine Scientists mull clues “VIPIT” syndrome challenge: Mutations vaccine jackpot memes may raise vaccination campaign and ICU numbers rollout linked to seeks vaccine stockpile vaccines; viral sequencing match COVID-19 of cases leaves rank for safety nears 500,000 Spanish Flu to many mutations sweep much of dubious claims over for T-cell test after lockdown exit vaccine woes the main vaccines in 15 US states safe and effective on virus’ origin associated with rise along with cases for rare extra doses money for charity going in your state? are dropping infection fall clearance with FDA Africa is being How is your vaccines? experts stumped during COVID the COVID pandemic the world Covid-19 cases in new trial data AztraZeneca vaccine left behind state doing? Feb.Mar. 16,17, 2021 Feb.Mar. 19,17, 2021 Feb. 17,22, 2021 Feb. 17,28, 2021 Feb.Mar. 17,9, 2021 2021 Feb.Mar. 17,11, 2021 Feb.Mar. 14,17, 2021 Feb.Mar. 26,17, 2021 Jan. 31, 2021 Feb. 2, 2021 Feb. 5, 2021 Feb. 14, 2021 Feb.Mar. 23,17, 2021 Jan. 20, 2021 Jan. 22, 2021 Jan. 25, 2021 Jan. 28, 2021 Feb. 16, 2021 Feb. 17,20, 2021 Feb. 17,25, 2021 Feb.Mar. 17,3, 2021 2021 Feb.Mar. 17,5, 2021 2021 Signs the pandemic Feb.Mar. 29,17, 2021 Feb. 7, 2021 South African UK Study: Novavax UK variant detected Thai PM gets Two emerging Feb.
Recommended publications
  • 23 April 2020 Update
    20 April – 23 April 2020 Contents I. Summary .............................................................................................................................1 II. European Union .................................................................................................................5 III. France ...............................................................................................................................6 IV. Italy ...................................................................................................................................7 V. Germany ............................................................................................................................8 VI. Spain ...............................................................................................................................10 VII. United Kingdom .............................................................................................................10 I. SUMMARY Number of cases: 1,009,762 (including the UK) Number of deaths: 108,223 • The EU Executive Steering Group on Shortages of Medicines Caused by Major Events held a meeting on 15 April to discuss the progress of the measures regarding availability of medicines for European patients during the COVID-19 pandemic. They also updated the Q&A document on regulatory expectations for medicinal products for human use during the COVID-19 pandemic on 20 April. On 21 April, they set-up the fast-track system to support essential medicines for COVID-19 treatment,
    [Show full text]
  • Written Evidence from Spotlight on Corruption1 (PGG18) the Public
    Written evidence from Spotlight on Corruption1 (PGG18) The Public Administration and Constitutional Affairs Committee Propriety of governance in light of Greensill inquiry Introduction The revelations arising from the Greensill affair and its fallout, coming alongside other recent and ongoing scandals, have exposed significant weaknesses in the UK system for managing conflicts of interest, lobbying, and business appointments. This is a vital opportunity to bring the UK’s standards landscape up to date, and to ensure that integrity and ethics in government are regulated in a way that befits a modern democracy. Taking action to strengthen the UK’s integrity and ethics framework would benefit the UK by helping to: build trust in politicians and government; strengthen the stability, predictability and attractiveness of the UK as a place to do business; give the UK greater credibility on the international stage in promoting democracy and good governance; and implement outstanding recommendations made by international bodies such as the UN and Council of Europe about how the UK can improve its integrity and ethics framework to prevent and tackle corruption. Key Recommendations 1. Integrity and Ethics legislation. The government should consult on the introduction of an Integrity and Ethics Bill, by the spring of 2022, which gives legislative effect to: the Law Commission’s recommendations on the introduction of a corruption in public office offence; recommendations made by international bodies to put ACOBA and the Independent Advisor on Ministerial Interests on a statutory footing; recommendations that are likely to be made by the Committee on Standards in Public Life’s Standards Matters 2.0 review in the Autumn of 2021; and recommendations likely to be made from both the Boardman review and parliamentary committees such as PACAC, including legislative reform to the Lobbying Act.
    [Show full text]
  • UK COVID-19 Vaccines Delivery Plan
    UK COVID-19 vaccines delivery plan Published 11 January 2021 Contents 1. Ministerial foreword ....................................................................................................... 3 2. Executive summary and scope ..................................................................................... 4 Supply .............................................................................................................................. 5 Prioritisation ...................................................................................................................... 6 Places ............................................................................................................................... 7 People .............................................................................................................................. 8 Tracking our progress ....................................................................................................... 9 3. Supply ......................................................................................................................... 10 Developing new vaccines ............................................................................................... 10 Ensuring vaccines meet strict safety standards for deployment ..................................... 17 Building UK manufacturing capability ............................................................................. 21 4. Prioritisation ...............................................................................................................
    [Show full text]
  • Legal-Graphics' 2-19-21 COVID Timeline
    Number of days Overview: Year 2 of COVID since first sign of virus Nov. 23, 2020 Dec. 3, 2020 Dec. 11, 2020 Dec. 21, 2020 Dec. 30, 2020 Worldwide Worldwide Worldwide Worldwide Worldwide Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Link to Source over 1,400,000 over 1,500,000 over 1,600,000 over 1,700,000 over 1,800,000 Signs of Virus 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 Key Events Nov. 16, 2020 Nov. 18, 2020 Nov. 21, 2020 Nov. 25, 2020 Nov. 27, 2020 Nov. 30, 2020 Dec. 3, 2020 Dec. 6, 2020 Dec. 8, 2020 Dec. 11, 2020 Dec. 14, 2020 Dec. 17, 2020 Dec. 21, 2020 Dec. 22, 2020 Dec. 26, 2020 Dec. 29, 2020 Dec. 31, 2020 Jan. 3, 2021 Good News! Moderna says data FDA allows US cases top Picture of US Demand for live Moderna to request Map showing US UK gears up for Chart of cumulative Pfizer vaccine to be How do the Pfizer Vaccinations reach How the Pfizer Vaccines across Could AZD7442 Map showing How vaccinations Interactive US Map shows its vaccine 1st rapid virus test 12 million ... spread economy is Christmas trees emergency states with the huge vaccination number of deaths OK’d in days - and Moderna US nursing homes and Moderna the world prevent COVID-19 which countries were developed by county showing Legal Matters is more than that gives results 'faster' and 'broader' worrisome skyrockets amid authorization their highest number plan watched by country (by “normal” next fall vaccines work? vaccines compare infection have rolled out so quickly risk for COVID 94% effective at home than ever as virus toll of virus coronavirus vaccine of virus deaths by the world number of days in those exposed? a COVID-19 vaccine inflicts damage since 100 deaths Dec.
    [Show full text]
  • Emerging Leaders in Biosecurity Initiative
    Emerging Leaders in Biosecurity Initiative Class of 2017 A competitive fellowship program created to identify, develop, and provide networking opportunities Yearbook for the next generation of leaders in biosecurity. Emerging Leaders in Biosecurity Initiative Contents Letter: 3 Thomas V. Inglesby, Director; Anita Cicero, Deputy Director, Johns Hopkins Center for Health Security Executive Steering Committee 5 Class of 2017 Fellows 9-35 ELBI 2017 Year in Review 36-37 ELBI Program Staff 41 ELBI Alumni 42 Cover and Inside Cover Photo Overlay: Swine Flu Strain Virus Particles. Col- orized transmission electron micrograph of negatively stained SW31 (swine strain) influenza virus particles. Credit: NIAID Emerging Leaders in Biosecurity Initiative The ELBI Fellowship program is made possible through financial support from the Open Philanthropy Project, under management by the Johns Hopkins Center for Health Security, and with the leadership of the ELBI Executive Steering Committee. For more information, please visit the ELBI website: http://www.centerforhealthsecurity.org/our-work/emergingbioleaders Center for Health Security “Modern conditions make the scenario of a global pandemic more likely. Humans are encroaching on animal environments, raising chances for pathogens to adapt from animals to people. An increasing share of the planet lives in megacities, heightening the likelihood of person-to-person transmission of pathogens. The movement of people and microbes around the globe is more efficient than ever. The recent outbreaks of SARS, MERS, and Ebola are only small glimpses of how quickly a deadly virus can spread.” Tom Inglesby and Benjamin Haas Foreign Affairs November 21, 2017 Middle East Respiratory Syndrome Coronavirus particle envelope proteins immunolabeled with Rabbit HCoV-EMC/2012 primary antibody and Goat an- 1 ti-Rabbit 10 nm gold particles.
    [Show full text]
  • SYRA MADAD, D.H.Sc, M.Sc., MCP
    SYRA MADAD, D.H.Sc, M.Sc., MCP Syra Madad, D.H.Sc., M.Sc., MCP is nationally recognized leader in public health and special pathogen preparedness and response. She is Senior Director, System-wide Special Pathogens Program at New York City Health + Hospitals, the nation’s largest municipal healthcare delivery system overseeing special pathogen preparedness and response efforts across 11 acute care hospitals in addition to post-acute/long-term care facilities and ambulatory care sites. She is Principal Investigator of NYC Health + Hospitals Center for Global Healthcare Preparedness to Special Pathogens. In addition, Dr. Madad is Core Faculty in the National Ebola Training and Education Center (NETEC), funded by the Centers for Disease Control and Prevention (CDC) and the Assistant Secretary for Preparedness and Response (ASPR) and Assistant Professor in the Graduate Biotechnology/Biodefense Program at the University of Maryland. She is an Alumni Fellow at Johns Hopkins Bloomberg School of Public Health, Center for Health Security’s Emerging Leaders in Biosecurity Program and the Federal Bureau of Investigation’s Behavioral Informatics & Technological Enterprise Studies Program. Dr. Madad earned her Doctoral degree in Health Science with a concentration in Global Health from Nova Southeastern University, graduating with Alpha Eta Health Science Honor Society status. She obtained her Master of Science degree in Biotechnology with a concentration in Biodefense and Biosecurity and Bachelor of Science degree in Psychology from the University of Maryland. Dr. Madad holds numerous professional certifications, licenses and training certificates including Master Continuity Practitioner Certification (FEMA), Advanced Emergency Planning Certification, All Hazard Response (CBRNE) Training for Laboratory Personnel, Biosafety Level III Training, and Identification of the Primary Select Agents of Bioterrorism Training.
    [Show full text]
  • La Verdad De La Pandemia Os Gusta Y Seguís Siendo Mis Mecenas, Pronto Nos Pondremos a Trabajar En El Siguiente Libro
    Índice Portada Sinopsis Dedicatoria Cita INTRODUCCIÓN. EL PRINCIPIO DEL CAOS PRIMERA PARTE. HECHOS 1. «TODO ESTÁ BAJO CONTROL» The Economist dixit Wuhan: un suceso local de alcance global El banco de virus más grande de Asia Cifras y muertes que no cuadran… La «orden»: confinamiento de la población El confinamiento de Wuhan… … Y China tiene el control El papel de la OMS Un espejo para comprender: Taiwán 2. HISTORIA DE UNA INFAMIA La OMS se alinea con el poder El «profeta»Tedros Adhanom La ideología del poder: el «Informe Kissinger» y los globócratas Nos matan con vacunas: la infertilidad de las mujeres Gursaran Pran Talwar y la vacuna anticonceptiva Bill Gates, vacunas y demografía La pandemia de Bill Gates La vacuna de Gates para el coronavirus SEGUNDA PARTE. LA IDEOLOGÍA DE LA ÉLITE 3. LABORATORIOS DE MANIPULACIÓN SOCIAL La Escuela de Chicago Mass Communication Research La Escuela de Fráncfort Tavistock Institute Estudios Culturales Método crítico versus colaboración con la superélite El MIT: el laboratorio actual Alex Pentland, el gurú de la élite globalista El MIT como faro de la élite Los amos del mundo iniciaron el camino: el Club Bilderberg 4. MEDIOS DE COMUNICACIÓN Y MENTIRAS Poder y comunicación: algunos apuntes históricos La Antigüedad La Edad Media La Edad Moderna La Edad Contemporánea Comunicación y cultura de masas Manipulación y propaganda El poder del cine La globalización: ¿quién tiene el poder? La «sociedad red» La comunicación en la «sociedad red» Normópatas El poder mediático y sus tentáculos La ideología de los medios de comunicación y la creación de alianzas Alphabet (Google), Amazon, Facebook, Apple, Microsoft y Netflix La sociedad domesticada con el mensaje único Los grandes conglomerados mediáticos y el Club Bilderberg Jeff Bezos, The Washington Post y Amazon Eric Schmidt, YouTube y Google Facebook, mucho más que una red social Mark Zuckerberg y Bilderberg: los dueños de Facebook Los jueces TERCERA PARTE.
    [Show full text]
  • COVID-19 Interim Vaccination Plan V.5 Pennsylvania
    COVID-19 Interim Vaccination Plan V.5 Pennsylvania PA COVID-19 Vaccine Task Force/PA Department of Health JANUARY 19, 2021 |VERSION 5.0 PENNSYLVANIA COVID-19 INTERIM VACCINATION PLAN Table of Contents Introduction……………………………………………………………………………………………………………………………………….2 Section 1: COVID-19 Vaccination Preparedness Planning ......................................................................... 3 Section 2: COVID-19 Organizational Structure and Partner Involvement ................................................. 4 Section 3: Phased Approach to COVID-19 Vaccination ........................................................................... 11 Section 4: Critical Populations ................................................................................................................. 17 Section 5: COVID-19 Provider Recruitment and Enrollment ................................................................... 21 Section 6: COVID-19 Vaccine Administration Capacity ........................................................................... 25 1. Health and Medical Infrastructure .......................................................................................... 25 2. Occupational Health Clinics and Closed Points of Dispensing (PODs) ..................................... 26 3. Expanded Outreach to Ensure Vaccine Access ........................................................................ 27 4. Staffing ....................................................................................................................................
    [Show full text]
  • Role and Responsibilities of the Chair of the Vaccine Taskforce
    Chair of the Vaccine Taskforce Information pack for applicants Closing date: Midday on Friday 14 May 2021 Reference no: VAC-1775 Follow us on Twitter @appointmentsdh Table of Contents Section 1: Role, responsibilities and person specification.................................................... 2 Section 2: How to apply ....................................................................................................... 4 2.1 Making an application ............................................................................................. 4 2.2 The selection process ............................................................................................. 7 2.3 Eligibility criteria ...................................................................................................... 9 2.4 How we will manage your personal information .................................................... 10 Chair of the Vaccine Taskforce - Information pack for applicants Section 1: Role and responsibilities of the Chair of the Vaccine Taskforce The Chair must enable the Vaccine Taskforce to achieve their three core objectives during the pandemic period: a. To secure access to promising vaccine/s for the UK population. b. To make provision for international distribution of vaccines. c. To strengthen the UK’s onshore capacity and capability in vaccine development, manufacturing, and supply chain to provide resilience for this and future pandemics. In recognising that the Taskforce has now been in existence for over a year, delivering these objectives
    [Show full text]
  • Clinical Laboratory Preparedness and Response Guide
    TABLE OF CONTENTS Table of Contents ...................................................................................................................................................................................... 2 State Information ....................................................................................................................................................................................... 7 Introduction .............................................................................................................................................................................................. 10 Laboratory Response Network (LRN) .......................................................................................................................................... 15 Other Emergency Preparedness Response Information: .................................................................................................... 19 Radiological Threats ......................................................................................................................................................................... 21 Food Safety Threats .......................................................................................................................................................................... 25 BioWatch Program ............................................................................................................................................................................ 27 Bio Detection Systems
    [Show full text]
  • Edical Sciences Esearch (IJAMSCR)
    Dr. N. Sriram et al / Int. J. of Allied Med. Sci. and C lin. Research Vol-9(1) 2021 [ 1-10] International Journal of Allied Medical Sciences and Clinical Research (IJAMSCR) ISSN: 2347 -6567 IJAMSCR |Volume 9 | Issue 1 | Jan - Mar - 2021 www.ijamscr.com Review article Medical research Development of new covid -19 vaccines from india : A systematic review 1Dr. N. Sriram, 2S. Kameshwaran , 3Asokkumar DS , 4N. Elavarasan, 5M. Sarbudeen 1Department of Pharmaceutics, Hits College of Pharmacy, Bogaram, Ghatkesar, Hyderabad, Telangana, India 2-5 Excel college of Pharmacy, Komarapalayam, Namakkal, Tamilnadu – 637303. *Corresponding Author :Dr. N. Sriram email: [email protected] ABSTRACT Extreme acute respiratory syndrome Coronavirus 2 (SARS -CoV-2) is an extremely pathogenic new virus that has triggered the current worldwide coronavirus disease pandemic (COVID -19). Currently, substantial effort has been made to produce successful and safe medicines and SARS-CoV-2 vaccines. To avoid more morbidity and death, a successful vaccine is important. Though some regions which deploy COVID -19 vaccines on the basis of protection and immunogenicity data alone, the aim of vaccine research is to obtain d irect proof of vaccine effectiveness in protecting humans against SARS-CoV -2 and COVID-19 infections in order to selectively increase the production of effective vaccines. A SARS-CoV-2 candidate vaccine can function against infection, illness, or transmiss ion and a vaccine that is capable of minimising all of these components may lead to disease control. In this study, we discussed the Bharat Biotech and Covishield Serum Institute of India's Covaxin - India's First Indigenous Covid -19 Vaccine.
    [Show full text]
  • 'Astrazeneca' Covid-19 Vaccine
    Medicines Law & Policy How the ‘Oxford’ Covid-19 vaccine became the ‘AstraZeneca’ Covid-19 vaccine By Christopher Garrison 1. Introduction. The ‘Oxford / AstraZeneca’ vaccine is one of the world’s leading hopes in the race to end the Covid-19 pandemic. Its history is not as clear, though, as it may first seem. The media reporting about the vaccine tends to focus either on the very small (non-profit, academic) Jenner Institute at Oxford University, where the vaccine was first invented, or the very large (‘Big Pharma’ firm) AstraZeneca, which is now responsible for organising its (non-profit) world-wide development, manufacture and distribution. However, examining the intellectual property (IP) path of the vaccine from invention to manufacture and distribution reveals a more complex picture that involves other important actors (with for-profit perspectives). Mindful of the very large sums of public money being used to support Covid-19 vaccine development, section 2 of this note will therefore contextualise the respective roles of the Jenner Institute, AstraZeneca and these other actors, so that their share of risk and (potential) reward in the project can be better understood. Section 3 provides comments as well as raising some important questions about what might yet be done better and what lessons can be learned for the future. 2. History of the ‘Oxford / AstraZeneca’ vaccine. 2.1 Oxford University and Oxford University Innovation Ltd. The Bayh-Dole Act (1980) was hugely influential in the United States and elsewhere in encouraging universities to commercially exploit the IP they were generating by setting up ‘technology transfer’ offices.
    [Show full text]